Navigation Links
Proove Biosciences Will Participate at the California Society of Interventional Pain Physician’s 4th Annual Meeting This Weekend
Date:9/20/2013

Irvine, CA (PRWEB) September 20, 2013

Proove Biosciences, Inc., the leading personalized pain medicine laboratory, is excited to announce that they will be attending and exhibiting at the California Society of Interventional Pain Physician’s 4th Annual Meeting this weekend at the Terranea Resort in Rancho Palos Verdes, California. The event will be held from September 20th to September 22nd.

CASIPP is a growing advocacy society working for interventional pain management physicians and their staff within the state of California. The organization’s mission is to promote the development and practice of safe, high quality, cost-effective interventional pain medicine techniques for the diagnosis and treatment of pain and related disorders, and ensure patient access to these interventions.

“We are proud to support Dr. Ray d'Amours, the President and Executive Director of CASIPP in this important conference,” explains Proove CEO and founder, Brian Meshkin. “Proove is a research-driven company committed to realizing the potential of personalized pain medicine. We are proud to stand with Dr. d’Amours and his colleagues at the forefront of pain medicine genetics. We continue to be the only company to present clinical research on the genetics of pain medicine at scientific meetings throughout the year including, PAINWeek, the American Pain Society, American Society of Addiction Medicine, and other major scientific meetings on pain management.”

Proove Biosciences will be exhibiting at CASIPP and sharing information on its proprietary genetic testing services, including the Proove Narcotic Risk Genetics test that helps physicians identify genetic predisposition to misuse of prescription narcotic pain medications and the Proove Drug Metabolism Genetics test that helps physicians understand the genetic predisposition to drug metabolism.

The meeting will consist of a variety of lectures, workshops, and speakers that cover topics ranging from pain management and therapy optimization, to the current political landscape of California pain management and treatment. Additionally, there will be opportunities for Continued Medical Education (CME) credit.

About Proove Biosciences
Proove Biosciences is the leading Personalized Pain Medicine laboratory that provides proprietary genetic testing services to help physicians improve outcomes for patients and contain costs for insurers. With offices in Southern California and the Baltimore-Washington metropolitan area, the Company is the research leader investigating and publishing data on the genetics of pain medicine with clinical research sites across the United States. Physicians use Proove Biosciences testing to improve pain medicine selection, dosing, and evaluation of medications they prescribe. From a simple cheek swab collected in the office, Proove performs proprietary genetic tests in its CLIA-certified laboratory to identify patients at risk for misuse of prescription pain medications and evaluate their metabolism of medications. For more information, please visit http://www.proovebio.com or call toll free 855-PROOVE-BIO (855-776-6832).

Read the full story at http://www.prweb.com/releases/2013/9/prweb11139959.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
5. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
9. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
10. Ambit Biosciences to Present at Two Upcoming Investor Conferences
11. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... Plate® YM (Yeast and Mold) microbial test has received AOAC Research Institute approval ... of microbial tests introduced last year,” stated Bob Salter, Vice President of Regulatory ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... NC (PRWEB) , ... June 23, 2016 , ... In ... University Hospital in Denmark detail how a patient who developed lymphedema after being treated ... tissue. The results could change the paradigm for dealing with this debilitating, frequent side ...
Breaking Biology Technology:
(Date:6/1/2016)... , June 1, 2016 ... in Election Administration and Criminal Identification to Boost Global ... a recently released TechSci Research report, " Global Biometrics ... Region, Competition Forecast and Opportunities, 2011 - 2021", the ... billion by 2021, on account of growing security concerns ...
(Date:5/20/2016)... May 20, 2016  VoiceIt is excited to ... VoicePass. By working together, VoiceIt and ... VoiceIt and VoicePass take slightly different approaches to ... both security and usability. ... this new partnership. "This marketing and ...
(Date:5/12/2016)... , May 12, 2016 WearablesResearch.com ... just published the overview results from the Q1 wave ... the recent wave was consumers, receptivity to a program ... data with a health insurance company. "We ... to share," says Michael LaColla , CEO of ...
Breaking Biology News(10 mins):